Uniqure NV
NASDAQ:QURE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Uniqure NV
Free Cash Flow
Uniqure NV
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Uniqure NV
NASDAQ:QURE
|
Free Cash Flow
-$178.4m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-80%
|
|
|
Pharming Group NV
AEX:PHARM
|
Free Cash Flow
$54m
|
CAGR 3-Years
38%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Free Cash Flow
-€53.8m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-8%
|
|
|
argenx SE
XBRU:ARGX
|
Free Cash Flow
$308.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merus NV
NASDAQ:MRUS
|
Free Cash Flow
-$318.6m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-29%
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Free Cash Flow
-$19.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
Uniqure NV
Glance View
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
See Also
What is Uniqure NV's Free Cash Flow?
Free Cash Flow
-178.4m
USD
Based on the financial report for Dec 31, 2025, Uniqure NV's Free Cash Flow amounts to -178.4m USD.
What is Uniqure NV's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-80%
Over the last year, the Free Cash Flow growth was 4%. The average annual Free Cash Flow growth rates for Uniqure NV have been -3% over the past three years , -4% over the past five years , and -80% over the past ten years .
